FDA Approves Antihemophilic Factor Preparation
A recombinant antihemophilic factor preparation produced by human cells has been approved by the FDA for use in patients who have hemophilia A. According to the product labeling, it is intended to provide “on-demand” treatment and control of bleeding episodes. It is also intended to help with routine bleeding prophylaxis and the management of bleeding […]
